^
Association details:
| Biomarker: | CD5 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma
Excerpt:
In CD5+ DLBCL, PFS and OS in patients treated with rituximab were significantly better than those without rituximab. Three-year PFS was 41.1% for the former and 15.4% for the latter (P=0.036, Fig. 1E), and three-year OS were 60.7 and 46.2% (P=0.047, Fig. 1F).
DOI:
https://doi.org/10.1182/blood-2019-127666
